research Dermatologia e Procedimentos Estéticos Ed. XVIII
Peptides improve skin health and treatments for hair loss and pregnancy-related skin issues are evolving.
Search
for
Sort by
Research
120-150 / 1000+ results research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
research Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
research A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis
Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
research Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
Leflunomide and anthralin may effectively treat severe alopecia areata.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Successful treatment of severe diffuse alopecia areata with abrocitinib
Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Upadacitinib is effective in treating psoriasis combined with lichen planus: a case report
Upadacitinib effectively treats psoriasis and lichen planus together.
research Alopecia areata in a patient receiving infliximab
Infliximab may cause hair loss in Crohn's disease patients.
research S3909 Paradoxical Psoriasis and Alopecia Areata After the Use of Anti-TNF in a Patient With Crohn's Cisease
Switching from infliximab to Ustekinumab improved both hair loss and Crohn's symptoms in the patient.
research Molecular Predictors of Ritlecitinib Efficacy in Alopecia Areata: Role of JAK3-Dependent Inflammation and Follicular Integrity
Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research 260 Anti-OX40 monoclonal antibody IMG-007 exhibited clinical activity of hair regrowth, suppressed scalp inflammatory biomarkers in patients with severe alopecia areata in a Ph1b/2a study
IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.